# A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Study · id `cardio:ct-nct01280695` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01280695](<https://clinicaltrials.gov/study/NCT01280695>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01280695

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

## Technical summary

Registry record NCT01280695. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2013-12-20.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT01280695, source copy `cardio:ctgov-nct01280695-2014-04-14`, retrieved 2026-10-26)
- Start date: 2011-02 (registry gives no type) (ClinicalTrials.gov record NCT01280695, source copy `cardio:ctgov-nct01280695-2014-04-14`, retrieved 2026-10-26)
- Primary completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01280695, source copy `cardio:ctgov-nct01280695-2014-04-14`, retrieved 2026-10-26)
- Completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01280695, source copy `cardio:ctgov-nct01280695-2014-04-14`, retrieved 2026-10-26)
- Results first posted: 2013-12-20 (ClinicalTrials.gov record NCT01280695, source copy `cardio:ctgov-nct01280695-2014-04-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01280695, source copy `cardio:ctgov-nct01280695-2014-04-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01280695-2014-04-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo
- Intervention (Drug): MSDC-0602 100 mg
- Intervention (Drug): MSDC-0602 250 mg
- Intervention (Drug): MSDC-0602 250 mg
- Intervention (Drug): Pioglitazone
- Lead sponsor: Metabolic Solutions Development Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 48eb380f12bcd00427038d38309b11266426cb43055e6f90f1c51ee177b036f7
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
